Trials (Oct 2023)

Community-based type 2 diabetes care by lay village health workers in rural Lesotho: protocol for a cluster-randomized trial within the ComBaCaL cohort study (ComBaCaL T2D TwiC)

  • Felix Gerber,
  • Ravi Gupta,
  • Thabo Ishmael Lejone,
  • Thesar Tahirsylaj,
  • Tristan Lee,
  • Maurus Kohler,
  • Maria Ines Haldemann,
  • Fabian Räber,
  • Mamakhala Chitja,
  • Molulela Manthabiseng,
  • Makhebe Khomolishoele,
  • Mota Mota,
  • Matumaole Bane,
  • Pauline Mamorontsane Sematle,
  • Retselisitsoe Makabateng,
  • Madavida Mphunyane,
  • Sejojo Phaaroe,
  • Dave Basler,
  • Kevin Kindler,
  • Eleonora Seelig,
  • Matthias Briel,
  • Frédérique Chammartin,
  • Niklaus Daniel Labhardt,
  • Alain Amstutz

DOI
https://doi.org/10.1186/s13063-023-07729-8
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Type 2 diabetes (T2D) poses a growing public health burden, especially in low- and middle-income countries (LMICs). Task-shifting to lay village health workers (VHWs) and the use of digital clinical decision support systems (CDSS) are promising approaches to tackle the current T2D care gap in LMICs. However, evidence on the effectiveness of lay worker-led T2D care models, in which VHWs initiate and monitor drug treatment in addition to community-based screening and referral services, is lacking. Methods We are conducting a cluster-randomized trial nested within the Community-Based Chronic Disease Care Lesotho (ComBaCaL) cohort study (NCT05596773) using the trial within cohort (TwiC) design to assess the effectiveness of a VHW-led, CDSS-assisted T2D care model in rural Lesotho. Participants are non-pregnant members of the ComBaCaL cohort study with T2D. The ComBaCaL cohort study is conducted in approximately 100 villages in two rural districts in Lesotho and is managed by trained and supervised VHWs. In intervention villages, VHWs offer a community-based T2D care package including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS to participants who are clinically eligible, as well as treatment support to participants who prefer or clinically require facility-based T2D care. In control clusters, all participants will be referred to a health facility for T2D management. The primary endpoint is the mean glycosylated haemoglobin (HbA1c) 12 months after enrolment. Secondary endpoints include the 10-year risk for cardiovascular events estimated using the World Health Organization risk prediction tool. Discussion The trial was launched on May 13, 2023, and has enrolled 226 participants at the date of submission (October 6, 2023). To our knowledge, the trial is the first to assess task-shifting of T2D care to VHWs at the community level, including the prescription of first-line antidiabetic, lipid-lowering, and antiplatelet medication in sub-Saharan Africa, and will thus provide the missing evidence on the effectiveness of such a T2D care model in this setting. The study is operating within the established Lesotho VHW programme. Similar community health worker programmes which exist across sub-Saharan Africa may benefit from the findings. Trial registration ClinicalTrials.gov NCT05743387. Registered on February 24 2023.

Keywords